Internal Medicine, Hematology · Maywood, IL
NPI
1013144260
Since 2009
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2160 S 1st Ave
Maywood, IL, 60153
Phone (708) 216-9000
Groups this clinician bills Medicare through
Medicare paid, 2024
$71K
958 services
Medicare patients, 2024
211
Average age 71
Drug cost, 2024
$6.7M
893 prescriptions
Company payments, 2025
$42K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stephanie B Tsai was code 99215 (office e&m - established), 228 times for 86 patients. In total Stephanie B Tsai billed 958 services in 20 codes, and Medicare paid $71K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 228 | 86 | $105.26 | $24K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 221 | 108 | $13.22 | $2,921 |
| 99233 Hospital E&M - Subsequent | Facility | 184 | 27 | $97.43 | $18K |
| 99214 Office E&M - Established | Facility | 90 | 74 | $68.02 | $6,122 |
| 99215 Office E&M - Established | Office | 46 | 16 | $120.59 | $5,547 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 43 | 21 | $11.92 | $513 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 21 | 12 | $24.60 | $517 |
| 99239 Hospital Discharge Management | Facility | 14 | 13 | $93.66 | $1,311 |
| 99223 Hospital E&M - Initial | Facility | 14 | 13 | $142.34 | $1,993 |
| 99213 Office E&M - Established | Facility | 12 | 11 | $45.17 | $542 |
By year: 2022 $73K for 792 services; 2023 $75K for 742 services; 2024 $71K for 958 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 84165 Clinical Chemistry | 23 | 17 | $15.30 | $352 |
| 86334 Immunoassay | 22 | 16 | $15.41 | $339 |
| 84166 Clinical Chemistry | 18 | 14 | $15.41 | $277 |
| 86335 Immunoassay | 13 | 11 | $15.41 | $200 |
Medicare prescription drug claims, 2024
In 2024, the drug Stephanie B Tsai prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 102 prescriptions and refills. In total Stephanie B Tsai wrote 893 Medicare prescriptions that cost $6.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 102 | 102 | 19 | $1.4M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 79 | 116 | 18 | $350 |
| Hydroxyurea Generic | 62 | 119 | 14 | $1,313 |
| Acyclovir Generic | 62 | 86 | 16 | $817 |
| Imatinib Mesylate Generic | 45 | 49 | Under 11 | $5,252 |
| Venclexta Venetoclax | 45 | 45 | 13 | $200K |
| Valacyclovir Valacyclovir Hcl | 39 | 61 | Under 11 | $2,117 |
| Imbruvica Ibrutinib | 38 | 38 | Under 11 | $579K |
| Bosulif Bosutinib | 36 | 36 | Under 11 | $658K |
| Revlimid Lenalidomide | 33 | 33 | Under 11 | $591K |
| Rezurock Belumosudil Mesylate | 32 | 32 | Under 11 | $676K |
| Lenalidomide Generic | 28 | 28 | Under 11 | $488K |
| Fluconazole Generic | 17 | 27 | Under 11 | $1,000 |
| Idhifa Enasidenib Mesylate | 14 | 14 | Under 11 | $424K |
| Onureg Azacitidine | 12 | 12 | Under 11 | $312K |
Brand drugs: - claims; generic drugs: 485 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stephanie B Tsai $42K ($42K in general payments such as food, travel and fees) from 9 companies. The largest payer was Gamida Cell Inc. with $34K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.